Skip to main content
. Author manuscript; available in PMC: 2011 Oct 28.
Published in final edited form as: Clin Cancer Res. 2007 Mar 15;13(6):1775–1782. doi: 10.1158/1078-0432.CCR-06-1863

Table 2.

Patient cohorts and DLTs

Dose level Schedule 17-AAG dose (mg/m2) Cycle duration (d) Patients DLTs Description of DLTs
1 Daily × 5 5 21 1 0
2 Daily × 5 10 21 1 0
3 Daily × 5 20 21 2 0
4 Daily × 5 40 21 3 0
5 Daily × 5 80 21 7 2 Thrombocytopenia (1 pt), diarrhea/hepatitis (1 pt)
6 Daily × 5 56 21 3 0
7 Daily × 3 80 14 3 0
8 Daily × 3 112 14 8 1 Emesis (1 pt)
9 Daily × 3 157 14 4 2 Nausea (1 pt), dyspnea (1 pt)
10 Days 1, 4, 8, and 11 112 21 3 0
11 Days 1, 4, 8, and 11 157 21 4 0
12 Days 1, 4, 8, and 11 220 21 6 1 Hepatitis (1 pt)
13 Days 1, 4, 8, and 11 307 21 3 2 Seizure (1 pt), abdominal pain/nausea/fever (1 pt)
14 Days 1 and 4 150 21 3 0
15 Days 1 and 4 210 21 3 0